REA Buys Stake in Mortgage Lender as Rightmove Saga Continues
By Stuart Condie
SYDNEY--Australian property advertiser REA Group, which is trying to buy U.K. counterpart Rightmove in a multi-billion dollar deal, has agreed to buy a stake in local mortgage lender Athena Home Loans.
REA on Thursday said it would pay up to 62 million Australian dollars ($42.3 million) out of existing cash reserves to fund the acquisition of a 19.9% interest in the digital non-bank lender. REA will take two seats on Athena's board.
The property classifieds group has had a strategic partnership with Athena since 2022, distributing Athena's loans through REA's Mortgage Choice financial-services business.
The companies' Mortgage Choice-branded products delivered A$1.2 billion in settlements over the 12 months through June.
"An equity investment builds on the success of our innovative Mortgage Choice Freedom home-loan products and forms a strong alliance to support the delivery of our strategy," REA Chief Executive Owen Wilson said.
Rightmove on Wednesday rejected a third bid from News Corp-controlled REA Group, saying the latest A$8.05 billion offer still materially undervalues the company and its future prospects.
REA Group is controlled by News Corp, which owns Dow Jones & Co., the publisher of Dow Jones Newswires and The Wall Street Journal.
Write to Stuart Condie at stuart.condie@wsj.com
(END) Dow Jones Newswires
September 25, 2024 19:44 ET (23:44 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks